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Abstract
Objectives
We aimed to evaluate a wide spectrum of clinical features of adult patients with spondyloar-
thritis (SpA) whose initial manifestation was fever, using the Assessment of SpondyloArthri-
tis international Society (ASAS) classification criteria.
Methods
We retrospectively collected the electronic medical records of hospitalized SpA patients
who initially presented to the Severance Hospital (Seoul, Korea) with fever from January
2010 to May 2016. As a control group, we also recruited one-hundred consecutive patients
who were diagnosed with SpA in our outpatient clinic. Clinical features and laboratory find-
ings were compared in two patient groups.
Results
There were 26 patients who had fever as initial presentation of SpA (reactive arthritis 50%,
undifferentiated SpA 26.9%, ankylosing spondylitis 15.4%, enteropathic arthritis 3.8%, pso-
riatic arthritis 3.8%). Peripheral SpA was more common in febrile SpA patients than in con-
trol SpA patients (65.4% vs 24.0%, p<0.001). Febrile SpA patients were less frequently
HLA-B27 positive than control SpA patients (52.2% vs 77.0%, p<0.05). At baseline, sys-
temic inflammatory markers were significantly higher in the febrile SpA patients (white blood
cell count, 11.57 vs 7.81 cells/μL, p<0.001; erythrocyte sedimentation rate, 69.2 vs 41.0
mm/h, p<0.001; C-reactive protein, 109.6 vs 15.3 mg/L, p<0.001). The proportion of patients
treated with systemic steroids was significantly higher in febrile SpA patients (57.7% vs.
11.0%, p<0.001). The proportion of patients who visited rheumatology specialty was signifi-
cantly lower in febrile SpA patients than in control SpA patients (7.7% vs 59.0%, p<0.001).
Conclusion
Various subgroups of SpA can be presented with fever as an initial manifestation. Febrile
SpA patients demonstrated higher systemic inflammation and a lower chance to visit
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rheumatology in early stage. When evaluating febrile patients with any clinical features of
SpA, clinicians are advised to consider performing SpA-focused evaluation including HLA-
B27 or a simple sacroiliac joint radiograph.
Introduction
Spondyloarthritis (SpA) is a collective term to refer to a group of inflammatory joint diseases
characterized by the distinguishing features of axial arthritis, asymmetric peripheral arthritis,
dactylitis, and enthesitis. SpA subgroups are including ankylosing spondylitis (AS), psoriatic
arthritis (PsA), reactive arthritis (ReA), undifferentiated SpA, and enteropathic arthritis [1].
According to a recently developed classification criteria by the Assessment of SpondyloArthri-
tis international Society (ASAS), SpA is classified into axial SpA and peripheral SpA [2–4].
Axial SpA patients present characteristic symptoms of the axial skeleton (sacroiliac joints and
spine), while peripheral SpA patients present symptoms of peripheral arthritis, enthesitis, and/
or dactylitis [2,5].
SpA patients can be presented with a wide range of extra-articular symptoms such as skin
rash, diarrhea, and eye discomfort [6]. Although fever has been known to be associated with
certain subtypes of SpA such as ReA [7,8], fever as extra-articular manifestations of SpA has
not fully been understood. A recent study showed that 33% of patients with ReA had fever
when they came to hospital [8]. Although fever is not a common clinical feature of PsA or
enteropathic arthritis, patients with generalized pustular psoriasis or inflammatory bowel dis-
eases can be presented with fever during flare [9,10]. Recent findings suggest that although
SpA has a wide range of clinical subtypes, they share fundamental disease pathogenesis [11]
and there is a possibility that fever might be an extra-articular manifestation of SpA.
It is not that complicated to take care of febrile SpA patients in rheumatology clinic as long
as they have the correct diagnosis. However, when undiagnosed SpA patients come to hospital
with fever, it is not a straightforward case for primary care physicians or infectious disease spe-
cialists. In fact, SpA is difficult to diagnose when the patient’s main symptom is fever, often
resulting in hospitalization for further diagnostic workups. SpA patients often remain undiag-
nosed for weeks or months, resulting in a significant delay in the appropriate treatments [12].
In the present study, we report a comprehensive evaluation of clinical features of SpA whose
initial manifestation was fever, using ASAS classification criteria.
Materials and methods
Patient demographics
In the retrospective review of the electronic medical records in the Severance Hospital(Seoul,
Korea) from January 2010 to May 2016, we identified that twenty-six patients were newly
diagnosed with SpA while being admitted for the evaluation of undiagnosed fever (body
temperature> 37.8˚C) [13]. They were included in our study as febrile SpA patients. One hun-
dred patients who were newly diagnosed with SpA at the outpatient clinic were included as
control SpA patients. SpA patients with age<19 years were excluded. The medical records of
SpA patients were identified using the following International Classification of Disease codes:
M45.x (ankylosing spondylitis, AS), M07.39 (psoriatic arthritis, PsA), M00.99 (reactive arthri-
tis, ReA), M06.00 (seronegative spondyloarthropathy), M02.39 (Reiter disease), M13.99
(enteropathic arthritis), H20.9 (anterior uveitis, AnU), M08.99 (juvenile idiopathic arthritis),
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and M48.99 (undifferentiated spondyloarthritis, uSpA). This study was approved by the Insti-
tutional Review Board of Severance Hospital (4-2016-0659). The requirement to obtain
informed consent was waived because of the retrospective nature of the study.
Classification of SpA subgroups
We reviewed the electronic medical records of the SpA patients to determine whether they
meet the diagnostic criteria for SpA disease subgroups. We used the modified AS criteria for
the diagnosis of AS [14], and the Classification Criteria for Psoriatic Arthritis criteria for PsA
[15]. The diagnosis of ReA was made when the history of previous infections such as proven
genitourinary or gastrointestinal infection, and typical musculoskeletal involvements were
confirmed [16]. We excluded febrile SpA patients with evidence of active infections because it
was not clear whether fever was the manifestation of infection or SpA. Enteropathic SpA were
diagnosed when patients had inflammatory bowel disease with concurrent arthritis. When
patients had several SpA features that did not fit into a single particular SpA subgroup, they
were classified as undifferentiated SpA. All patients were classified into either axial or periph-
eral predominant SpA according to the ASAS classification criteria [2,3]. The flow chart of
SpA classification is shown in Fig 1.
Evaluation of clinical features
We reviewed the patients’ symptoms, physical findings, past medical history, and steroid use.
Symptom duration was defined as time between the onset of dominant symptoms and the
diagnosis of SpA. Symptoms can be eye discomfort, diarrhea, joint pain, back pain, skin rashes,
or fever. In addition, laboratory findings, such as aspartate transaminase (AST), alanine trans-
aminase (ALT), and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and
human leukocyte antigen (HLA)-B27 test, were evaluated at the time of diagnosis and at six
months. Radiographic studies of the sacroiliac joint were reviewed. We used radiographic cri-
terion based on modified New York criteria for AS which is sacroiliitis grade2 bilaterally or
sacroiliitis grade 3–4 unilaterally [14].
Statistical analysis
We utilized the independent sample t-tests for normally distributed parameters, Mann–Whit-
ney U test for non-normally distributed parameters, chi-squared test or Fisher’s exact test for
categorical parameters, and Wilcoxon matched pairs test for comparison of clinical features.
Statistical tests were two-sided. All statistical analyses were performed using IBM SPSS Statis-
tics 22.0 software (IBM SPSS Inc., Chicago, IL, USA).
Results
Baseline demographics
Twenty-six SpA patients who initially presented with fever (febrile SpA) and one-hundred
SpA patients diagnosed at the outpatient clinic (control SpA) were included. The mean ages of
febrile SpA patients and control SpA patients were 39.6 and 36.7 years, respectively (Table 1).
Male patients were 69.2% and 67.0% in each group. 7.7% of febrile SpA patients and 59.0% of
control SpA patients received their initial subspecialty evaluation at the rheumatology clinic
(p<0.001). The rest of febrile SpA patients were hospitalized by subspecialists in other depart-
ments such as emergency medicine (n = 16), infectious disease (n = 4), gastroenterology
(n = 1), nephrology (n = 1), neurosurgery (n = 1), and orthopedics (n = 1). The mean duration
Fever and spondyloarthritis
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Fig 1. Flow chart of study enrollment. Abbreviations: SpA, spondyloarthritis; IBD, inflammatory bowel disease.
https://doi.org/10.1371/journal.pone.0184323.g001
Fever and spondyloarthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0184323 September 14, 2017 4 / 10
of SpA symptoms was significantly seven-times shorter in febrile SpA patients than in control
SpA patients (20.19±15.95 vs 140.19±196.89, p<0.001).
Clinical features
We evaluated how many patients in each group had met the diagnostic criteria for SpA sub-
groups. AS was significantly less common in febrile SpA patients than in control SpA patients
(15.4% vs 76.0%, p<0.001, Table 2). ReA was significantly more common in the febrile SpA
Table 1. Baseline characteristics of the study participants.
Febrile SpA
(n = 26)
Control SpA
(n = 100)
p
Age, years 39.58±14.94 36.72±13.02 0.336
Male 18(69.2) 67(67.0) 0.829
Body mass index (kg/m2) 22.18±2.91 22.50±3.52 0.679
Duration of symptom, days 20.19±15.95 140.19±196.89 < 0.001
Direct referral to rheumatology 2 (7.7) 59(59.0) < 0.001
Data are presented as mean±SD or n (%).
Abbreviations: SpA, spondyloarthritis
https://doi.org/10.1371/journal.pone.0184323.t001
Table 2. Clinical features of febrile SpA patients.
Febrile SpA
(n = 26)
Control SpA
(n = 100)
p
Clinical subtypes
Ankylosing spondylitis 4 (15.4) 76 (76.0) < 0.001
Psoriatic arthritis 1 (3.8) 9 (9.0) 0.686
Reactive arthritis 13 (50.0) 5 (5.0) < 0.001
Enteropathic arthritis 1 (3.8) 1 (1.0) 0.371
Undifferentiated SpA 7 (26.9) 9 (9.0) 0.022
ASAS classification criteria
Axial SpA 9 (34.6) 76 (76.0) < 0.001
Peripheral SpA 17 (65.4) 24 (24.0) < 0.001
Peripheral joint involvement
Shoulder 7 (26.9) 16 (16.0) 0.158
Wrist & hand 3 (11.5) 25 (25.0) 0.103
Knee 12 (46.1) 21 (21.0) 0.023
Ankle & foot 5 (19.2) 15 (15.0) 0.359
Clinical findings
Fever 26 (100.0) 1 (1.0) < 0.001
Previous infection 13 (50.0) 6 (6.0) < 0.001
Uveitis 3 (11.5) 16 (16.0) 0.571
Good response to NSAIDs 13 (50.0) 63 (63.0) 0.227
Arthroscopic surgery 3 (11.5) 0 (0.0) 0.008
HLA-B27 12 (52.2)* 77 (77.0) 0.016
Sacroiliitis in X-ray 12 (66.7)** 90 (90.0) 0.008
Data are presented as n (%).
*Number confined to patients who underwent each test (n = 23).
**Number confined to patients who underwent each test (n = 18).
Abbreviations: NSAIDS, non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis
https://doi.org/10.1371/journal.pone.0184323.t002
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patients (50.0% vs 5.0%, p<0.001). Febrile SpA patients had peripheral SpA more commonly
than control SpA patients (65.4% vs 24.0%, p<0.001).
Laboratory parameters
At the baseline, AST, ALT, CRP, and ESR were significantly higher, and hemoglobin and albu-
min were significantly lower in febrile SpA patients (Table 3). At six months, lab results were
not significantly different between groups except CRP and hemoglobin.
Treatment
The proportion of patients treated with systemic steroids was significantly higher in febrile
SpA patients (at baseline, 57.7% vs 11.0%, p<0.001; after 6 months, 42.3% vs 22.0%, p = 0.046;
Table 4). The proportion of patients treated with nonsteroidal anti-inflammatory drugs
(NSAIDs) was significantly lower in febrile SpA patients (at baseline, 73.1% vs 95.0%,
p = 0.003; after 6 months, 69.2% vs 96.0%, p<0.001). There were no significant differences in
Table 3. Comparison of laboratory parameters of febrile and control SpA patients.
At baseline p At 6 months p
Febrile SpA
(n = 26)
Control SpA
(n = 100)
Febrile SpA
(n = 26)
Control SpA
(n = 100)
White blood cell (cells/μL) 11.57±5.95 7.81±2.35 < 0.001 7.47±2.81 7.10±2.15 0.467
Hemoglobin (g/dL) 12.45±1.94 14.11±1.69 < 0.001 13.35±2.15 14.31±1.46 0.008
Platelet (×1,000/μL) 339.15±127.06 301.17±94.72 0.093 288.58±86 269.44±67.13 0.226
Total protein (mg/dL) 6.92±0.93 7.30±0.52 0.006 7.05±0.84 7.17±0.38 0.299
Albumin (mg/dL) 3.70±0.59 4.25±0.41 < 0.001 4.32±0.73 4.41±0.26 0.308
Creatinine (mg/dL) 0.86±0.49 0.75±0.16 0.083 1.00±0.96 0.78±0.17 0.033
AST (IU/L) 32.85±23.52 18.77±9.07 < 0.001 19.19±7.69 20.17±8.73 0.604
ALT (IU/L) 42.20±33.06 19.26±15.31 < 0.001 20.73±15.50 19.44±13.18 0.669
ESR (mm/h) 69.23±38.20 41.00±31.10 < 0.001 29.15±29.82 20.51±18.62 0.068
CRP (mg/L) 109.62±90.73 15.31±21.57 < 0.001 18.98±49.34 4.18±7.00 0.004
Data are presented as mean±SD.
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; SpA,
spondyloarthritis; TNF, tissue necrosis factor
https://doi.org/10.1371/journal.pone.0184323.t003
Table 4. Comparison of treatment between the febrile group and the outpatient group.
At baseline p After 6 months p
Febrile SpA
(n = 26)
Control SpA
(n = 100)
Febrile SpA
(n = 26)
Control SpA
(n = 100)
NSAIDs 19 (73.1) 95 (95.0) 0.003 18 (69.2) 96 (96.0) < 0.001
Steroid 15 (57.7) 11 (11.0) < 0.001 11 (42.3) 22 (22.0) 0.046
Sulfasalazine 6 (23.1) 56 (56.0) 0.071 11 (42.3) 67 (67.0) 0.025
Methotrexate 3 (11.5) 4 (4.0) 0.154 4 (15.4) 16 (16.0) 1.000
TNF inhibitors 0 0 N/A 5 (19.2) 11 (11.0) 0.320
Analgesics 4 (15.4) 6 (6.0) 0.213 5 (19.2) 8 (8.0) 0.140
Data are presented as n (%).
Abbreviations: N/A, not applicable; NSAIDS, non-steroidal anti-inflammatory drugs; SpA, spondyloarthritis; TNF, tumor necrosis factor
https://doi.org/10.1371/journal.pone.0184323.t004
Fever and spondyloarthritis
PLOS ONE | https://doi.org/10.1371/journal.pone.0184323 September 14, 2017 6 / 10
the proportions of patients taking tissue necrosis factor inhibitors and methotrexate in febrile
and control SpA patients. At 6 months, the proportion of patients taking sulfasalazine was
lower in febrile SpA patients than in control SpA patients (42.3% vs 67.0%, p = 0.025).
Discussion
SpA has wide range clinical manifestations from axial and peripheral musculoskeltal symp-
toms to non-specific systemic symptoms. It is clinically challenging to make the diagnosis of
SpA in patients with non-articular symptoms. A strikingly high number of SpA patients with
non-specific symptoms are misdiagnosed by clinicians, resulting in inappropriate or delayed
treatment [12,17]. According to a previous study, 50% of SpA patients with anterior uveitis
were diagnosed with SpA after they developed the eye symptoms [18]. We found that only
7.7% of febrile SpA patients (Table 1) received their initial subspecialty evaluation with rheu-
matologists, suggesting that many clinicians do not consider SpA in the evaluation of febrile
patients with extra-articular SpA symptoms. Furthermore, three febrile SpA patients (11.5%)
underwent unnecessary arthroscopic surgery (Table 2), because the clinicians suspected septic
arthritis in febrile SpA patients. However, we still lack a comprehensive understanding of clini-
cal features of febrile SpA.
In the present study, we have retrospectively reviewed the electronic medical records of
febrile hospitalized SpA patients. Febrile SpA patients were more likely to have peripheral
joint symptoms, and higher white blood cell (WBC) count, CRP, ESR, AST and ALT, and
lower total proteins, albumin, and hemoglobin than control SpA patients. Febrile SpA patients
were significantly more frequently treated with steroids, compared to control SpA patients.
At six months, most of the laboratory abnormalities returned to normal except for hemo-
globin, creatinine, and CRP. The proportion of patients taking steroids decreased in febrile
SpA patients while the proportion of patients taking steroids increased in control SpA patients.
It is probably because rheumatologists more easily decide to use steroid treatments when SpA
patients have fever and systemic inflammation, while they are reluctant to use steroids on SpA
patients with only joint pain in the early stage of treatment. However, after 6 months, when
control SpA patients did not respond to first-line treatment (NSAIDs, sulfasalazine and meth-
otrexate), the use of steroids might be increased. There were no significant differences in the
proportions of patients taking tissue necrosis factor inhibitors in febrile and control SpA
patients. This suggests that the prognoses of febrile SpA and control SpA patients are compara-
ble. Our result is different from a previous observation in a pediatric population where febrile
patients with enthesitis showed poor prognostic outcomes [19]. The discrepancy is likely due
to the differences in the disease progression between child-onset enthesitis and adult-onset
enthesitis.
In addition to conventional treatments such as NSAIDs and biologics, corticosteroid use in
SpA patients has been evaluated in several studies. While local corticosteroid injections have
been known to be an effective treatment in severe SpA [20,21], systemic use is not generally
recommended in the treatment of SpA [22]. In this study, the proportion of patients taking
systemic steroids in the febrile SpA group was higher than that in the control SpA group. Addi-
tionally, the use of NSAIDs, the first line therapy in SpA, is lower in febrile SpA patients proba-
bly related with higher use of steroids. Previous studies also suggested systemic steroid use in
refractory peripheral SpA patients [23,24].
The physician’s suspicion appears to be important for the early diagnosis of the SpA [25].
AS is the best-known form of SpA with its characteristic chronic inflammation of spine. How-
ever, in febrile SpA patients, the relatively small proportion of AS makes it difficult for clini-
cians to make the proper diagnosis. Furthermore, peripheral SpA was significantly more
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common in febrile SpA patients. The clinical picture of febrile patients with knee pain and
swelling can easily mislead clinicians to consider that the patients may have septic arthritis.
Therefore, it requires special attention to detect SpA in febrile patients. Radiographic sacroilii-
tis was frequently detected (66.7%) in the febrile SpA group. 52.2% of the febrile SpA patients
were positive for HLA-B27. A simple radiograph of the sacroiliac joints and the HLA-B27 test
can be cost-effective screening tools in febrile patients with any clinical features of SpA.
There are limitations to this study. First, the data for this study were collected retrospec-
tively, which may have led to bias in patient selection and analysis. Because it is not easy to
make proper diagnosis of SpA in febrile patients, there is a possibility that our study popula-
tion only represents a small portion of febrile SpA patients. Second, because this is an observa-
tional, cross-sectional study, the long-term prognostic outcomes were not evaluated. Third,
there is a possibility that the difference between the febrile group and the control group could
be associated with the disease severity because febrile SpA patients were treated as inpatient
while the control group patients were treated as outpatient. This could cause selection bias
because hospitalized patients were more thoroughly investigated including HLA-B27 tests.
Fourth, we could not confirm that SpA is the direct cause of fever and there is a possibility of
hidden concurrent infection. However, our patients had a thorough evaluation during hospi-
talization including infectious disease specialist consultation and there was no evidence of
infection. They were treated with steroids which made fever and clinical features of SpA
improved. After 6 months, 42.3% of febrile SpA patients were still taking steroids which dem-
onstrated that our febrile SpA patients did have severe systemic inflammation which requires
chronic use of steroids. These findings support that fever is associated with SpA. However, this
is the first clinical study to comprehensively evaluate the clinical features of febrile SpA
patients. When patients with fever have SpA-associated symptoms, SpA-focused evaluation
such as the HLA-B27 test and a simple radiograph of the sacroiliac joint are recommended.
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